Addex Therapeutics Ltd

NasdaqCM ADXN

Addex Therapeutics Ltd Price to Earnings Ratio (P/E) on December 30, 2024: 1.53

Addex Therapeutics Ltd Price to Earnings Ratio (P/E) is 1.53 on December 30, 2024, a 349.43% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Addex Therapeutics Ltd 52-week high Price to Earnings Ratio (P/E) is 2.63 on August 27, 2024, which is 72.03% above the current Price to Earnings Ratio (P/E).
Addex Therapeutics Ltd 52-week low Price to Earnings Ratio (P/E) is -2.30 on April 09, 2024, which is -250.22% below the current Price to Earnings Ratio (P/E).
Addex Therapeutics Ltd average Price to Earnings Ratio (P/E) for the last 52 weeks is 0.50.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: ADXN

Addex Therapeutics Ltd

CEO	Mr. Timothy Mark Dyer
IPO Date	Feb. 12, 2020
Location	Switzerland
Headquarters	Chemin des Mines, 9
Employees	23
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Key trends

Past 5 years